UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (State o ...

Exhibit 99.1 Kura Oncology Reports First Quarter 2024 Financial Results – Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – ...

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been gra ...

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Pete De Spain - Executive Vice President of Investor Relations Troy Wilson - President & CEO Tom Doyle - SVP of Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Li Watsek - Cantor Fitzgerald Peter Lawson - Barclays Justin Zelin - BTIG Reni Benjamin - Citizens JMP Brad Canino - Stifel Eva Privitera - TD Cowen Operator Good aft ...

KOMET-001 Phase 1/2 Study of Ziftomenib in Relapsed/Refractory AML Ziftomenib Demonstrates Optimal Pharmaceutical Properties • No dose adjustment of ziftomenib needed when administered with a CYP3A4 inhibitor (e.g., azoles) 10 • Rates of DS in KMT2A-r monotherapy patients were 38.5% at 200 mg and 37.5% at 600 mg; potential to mitigate in combination Fathi et al. EHA 2023 #LB2713 (preliminary data as of April 12, 2023) 11 40% of NPM1 patients achieved a CR during course of study High activity, durable respon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 61-1547851 (State or other jurisdiction of ...

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Pete De Spain - Head of Investor Relations Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President of Finance & Accounting Conference Call Participants Jason Zemansky - Bank of America Peter Lawson - Barclays Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Jeet Mukherjee - BTIG Phil Nadeau - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gent ...

Forecasted Milestones & Financial Highlights 32 | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Corporate Presentation – November 2023 | | | | | * Optimum biologically active dose ** Cash, cash equivalents and short-term investments 2 All forward-looking statements contained in this presentation speak only as of the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Indicate by check mark w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ (State or other jurisdiction ...